Data Driven Bioscience – Trademark Portfolio

Entity Type: 03

Data Driven Bioscience holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include DUOSEQ. The owner is based in Durham, NC.

701 W. Main St.

Durham, NC 27701

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

DUOSEQ
DUOSEQ
Registered 2021
DUOSEQ
DUOSEQ
Abandoned 2019

Trademark Classifications

Data Driven Bioscience's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Data Driven Bioscience have?

Data Driven Bioscience has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned.

What trademark classes does Data Driven Bioscience file in?

Data Driven Bioscience files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 10 (Medical Apparatus). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are Data Driven Bioscience's most well-known trademarks?

Data Driven Bioscience's registered trademark portfolio includes well-known marks such as DUOSEQ. These are among 1 currently registered trademark in the portfolio.

What is Data Driven Bioscience's trademark registration success rate?

Data Driven Bioscience has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.